Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

New hope for diabetics: Innovative treatment begins clinical trials at MUHC

11.02.2010
Study of new Exsulin TM peptide treatment for type 1 diabetes starts this month

A clinical trial of Exsulin, an innovative new treatment that targets the underlying cause of type 1 diabetes, has begun at the McGill University Health Centre (MUHC). Under the direction of Dr. George Tsoukas of the MUHC and the McGill University Faculty of Medicine, the study will assess the effectiveness of Exsulin.

This potentially groundbreaking therapy was made possible by fundamental research led by Dr. Lawrence Rosenberg of the MUHC and McGill University Faculty of Medicine. The study is conducted in partnership with the Mayo Clinic in Rochester, Minnesota.

Type 1 diabetes is triggered when a patient’s immune system attacks and destroys insulin-producing beta cells in the pancreas. This prevents normal insulin secretion and the normal regulation of blood sugar levels. There is currently no cure for type 1 diabetes and it can only be controlled through regular insulin injections. Although these injections partially avoid sugar level fluctuations in the blood they do not prevent the onset of other complications.

Dr. Rosenberg and his colleagues have been working on an Exsulin-based treatment to stimulate the regrowth of insulin-producing beta cells in diabetic patients for more than 25 years.

“Exsulin has already been tested in animal models of diabetes,” he explained. “These experiments demonstrated that Exsulin injections help restore insulin production in animals whose insulin production had been lost. For example, mice injected with this new molecule were cured of their diabetes.”

The results of previously conducted human trials have indicated that Exsulin triggers at least a partial recovery of natural insulin secretion. Although at this stage of development it may not completely control the amount of circulating glucose, Exsulin does improve glucose homeostasis, which prevents the dramatic fluctuations that can lead to the main complications of diabetes: neuropathy, renal failure, blindness and heart disease. This new clinical trial aims to test a new formulation of Exsulin and to establish the best dosing schedule, as well as the most effective dosage.

In vitro experiments on human pancreatic tissue have shown that Exsulin acts on stem-like cells by causing them to differentiate into new insulin-producing beta cells, as well as the three other types of endocrine cells that make up the islets of Langerhans. In a healthy pancreas, these “islets,” or small groups of cells, house all cells that produce glucagon, somatostatin, pancreatic polypeptide, as well as those that produce insulin.

“This means that Exsulin could help rebuild the islets’ entire structure, restoring near-normal metabolic control—something that insulin injections alone cannot do,” concluded Dr. Rosenberg.

Dr. Lawrence Rosenberg is Chief of the Division of Surgical Research, and Professor of Surgery and Medicine at McGill’s Faculty of Medicine. He holds the A.G. Thompson Chair in Surgical Research at the MUHC and is also an investigator in the Endocrinology, Diabetes, Nutrition and Kidney Diseases Axis of the Research Institute of the MUHC. Dr Rosenberg is also Chief of Surgical Services at the SMBD-Jewish General Hospital.

Dr. George Tsoukas is a senior member of the Department of Endocrinology at the MUHC and he currently supervises the Montreal General Hospital Diabetes Clinic at the MUHC. He is also a clinical investigator in the “Musculoskeletal Disorders” axis at the Research Institute of the MUHC and has been involved in many clinical trials involving diabetes and associated illnesses. Dr. Tsoukas is an Associate Professor in the Faculty of Medicine at McGill University.

Funding
This study will be partly funded by the MUHC Foundation, Montreal and Exsulin Corporation, Minneapolis in collaboration with Dr. Lawrence Rosenberg at the Research Institute of the MUHC.
On the Web
§ Research Institute of the McGill University Health Centre: www.muhc.ca/research
§ McGill University: www.mcgill.ca
§ Exsulin Corporation: www.exsulin.com
For more information please contact:
Julie Robert
Communications Coordinator (research)
MUHC Public Affairs and Strategic Planning
Telephone: 514- 843-1560
Email: julie.robert@muhc.mcgill.ca

Julie Robert | MUHC Public Affairs
Further information:
http://www.muhc.ca/research

More articles from Health and Medicine:

nachricht Minimising risks of transplants
22.02.2018 | Friedrich-Alexander-Universität Erlangen-Nürnberg

nachricht FAU researchers demonstrate that an oxygen sensor in the body reduces inflammation
22.02.2018 | Friedrich-Alexander-Universität Erlangen-Nürnberg

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Developing reliable quantum computers

International research team makes important step on the path to solving certification problems

Quantum computers may one day solve algorithmic problems which even the biggest supercomputers today can’t manage. But how do you test a quantum computer to...

Im Focus: In best circles: First integrated circuit from self-assembled polymer

For the first time, a team of researchers at the Max-Planck Institute (MPI) for Polymer Research in Mainz, Germany, has succeeded in making an integrated circuit (IC) from just a monolayer of a semiconducting polymer via a bottom-up, self-assembly approach.

In the self-assembly process, the semiconducting polymer arranges itself into an ordered monolayer in a transistor. The transistors are binary switches used...

Im Focus: Demonstration of a single molecule piezoelectric effect

Breakthrough provides a new concept of the design of molecular motors, sensors and electricity generators at nanoscale

Researchers from the Institute of Organic Chemistry and Biochemistry of the CAS (IOCB Prague), Institute of Physics of the CAS (IP CAS) and Palacký University...

Im Focus: Hybrid optics bring color imaging using ultrathin metalenses into focus

For photographers and scientists, lenses are lifesavers. They reflect and refract light, making possible the imaging systems that drive discovery through the microscope and preserve history through cameras.

But today's glass-based lenses are bulky and resist miniaturization. Next-generation technologies, such as ultrathin cameras or tiny microscopes, require...

Im Focus: Stem cell divisions in the adult brain seen for the first time

Scientists from the University of Zurich have succeeded for the first time in tracking individual stem cells and their neuronal progeny over months within the intact adult brain. This study sheds light on how new neurons are produced throughout life.

The generation of new nerve cells was once thought to taper off at the end of embryonic development. However, recent research has shown that the adult brain...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

2nd International Conference on High Temperature Shape Memory Alloys (HTSMAs)

15.02.2018 | Event News

Aachen DC Grid Summit 2018

13.02.2018 | Event News

How Global Climate Policy Can Learn from the Energy Transition

12.02.2018 | Event News

 
Latest News

Stiffness matters

22.02.2018 | Life Sciences

Magnetic field traces gas and dust swirling around supermassive black hole

22.02.2018 | Physics and Astronomy

First evidence of surprising ocean warming around Galápagos corals

22.02.2018 | Earth Sciences

VideoLinks
Science & Research
Overview of more VideoLinks >>>